Illumina, Inc. (NASDAQ:ILMN) CEO Francis A. Desouza sold 3,000 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $301.25, for a total value of $903,750.00. Following the sale, the chief executive officer now directly owns 64,200 shares of the company’s stock, valued at $19,340,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ:ILMN opened at $292.87 on Thursday. The firm has a market capitalization of $42.42 billion, a price-to-earnings ratio of 51.20, a price-to-earnings-growth ratio of 2.77 and a beta of 1.10. Illumina, Inc. has a 1-year low of $268.62 and a 1-year high of $380.76. The company has a quick ratio of 6.10, a current ratio of 6.79 and a debt-to-equity ratio of 0.42. The company’s fifty day simple moving average is $330.27.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.03. The firm had revenue of $838.00 million for the quarter, compared to analyst estimates of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. Illumina’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.43 earnings per share. As a group, sell-side analysts anticipate that Illumina, Inc. will post 6.04 earnings per share for the current year.
Several brokerages have recently commented on ILMN. Canaccord Genuity downgraded Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $330.00 to $300.00 in a report on Tuesday, July 30th. Credit Suisse Group reaffirmed a “buy” rating and set a $340.00 target price on shares of Illumina in a report on Wednesday, July 31st. BidaskClub downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 13th. Bank of America downgraded Illumina from a “buy” rating to an “underperform” rating and set a $310.00 target price for the company. in a report on Friday, July 12th. Finally, Piper Jaffray Companies reduced their target price on Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a report on Tuesday, July 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the stock. Illumina currently has a consensus rating of “Buy” and a consensus target price of $330.92.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Bond
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.